系統識別號 | U0002-1706201117470800 |
---|---|
DOI | 10.6846/TKU.2011.00580 |
論文名稱(中文) | 3,3'-二吲哚甲烷藉由降低 HER2/neu 誘使 HER2/neu 過表現卵巢癌和乳癌細胞凋亡 |
論文名稱(英文) | 3, 3’-diindolylmethane induces apoptosis through reduction of HER2/neu in HER2/neu-overexpressing ovarian and breast cancers |
第三語言論文名稱 | |
校院名稱 | 淡江大學 |
系所名稱(中文) | 化學學系碩士班 |
系所名稱(英文) | Department of Chemistry |
外國學位學校名稱 | |
外國學位學院名稱 | |
外國學位研究所名稱 | |
學年度 | 99 |
學期 | 2 |
出版年 | 100 |
研究生(中文) | 梁展帆 |
研究生(英文) | Chan-Fan Liang |
學號 | 697160892 |
學位類別 | 碩士 |
語言別 | 繁體中文 |
第二語言別 | |
口試日期 | 2011-05-19 |
論文頁數 | 73頁 |
口試委員 |
指導教授
-
莊子超
委員 - 許世忠 委員 - 陳銘凱 |
關鍵字(中) |
神經膠原致癌基因 3, 3'-二吲哚甲烷 |
關鍵字(英) |
HER2/neu 3,3'-diindolylmethe |
第三語言關鍵字 | |
學科別分類 | |
中文摘要 |
致癌基因 HER2/neu 過表現導致腫瘤細胞侵入、轉移和血管新生。文獻指出, 3,3’-二吲哚甲烷 (3,3’-diindolylmethane, DIM) 擁有抗癌活性。本實驗證實 DIM 能夠抑制 HER2/neu 表現的卵巢癌和乳癌細胞增生。本實驗結果顯示 DIM 在 HER2/neu 表現的卵巢癌和乳癌細胞中,能抑制 HER2/neu 和其下游 PI3K/Akt 訊號傳遞路徑,因此降低 HER2/neu 誘導的腫瘤轉移能力。此外從 PARP 被切斷的程度顯示 DIM 能促進卵巢癌和乳癌細胞凋亡。總和以上結果,本實驗為 DIM 的抗癌效應提出新的分子機制。 |
英文摘要 |
Overexpression of the HER2 oncogene contributes to tumor cell invasion, metastasis and angiogenesis. 3,3’-diindolylmethane (DIM) has been reported to exhibit anti-tumor activities. Here, we examined the anti-proliferating effects of DIM on HER2-positive ovarian and breast cancer cells. Our results demonstrated that DIM may inhibit HER2 and its downstream PI3K/Akt-signaling network, thus resulting in suppression of HER2-mediated metastatic potential in HER2-positive ovarian and breast cancers. Besides, DIM-induced apoptosis in HER2-positive ovarian and breast cancer cells was characterized by the up-regulation of cleaved poly(ADP-ribose) polymerase (PARP). Taken together, our data provide a new mechanism for the DIM-mediated anticancer effect. |
第三語言摘要 | |
論文目次 |
摘要 I 中文摘要 I 英文摘要 II 第一章 緒論 1 第一節 神經膠原致癌基因 (HER2/NEU) 1 第二節 3, 3’-二吲哚甲烷 11 第三節 實驗動機與目的 19 第二章 材料與方法 20 第三章 結果 29 第一節 實驗結果 29 第二節 實驗圖表 35 第四章 討論 46 第五章 參考文獻 49 附錄 68 |
參考文獻 |
Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S (2006). 3,3'- diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27: 717-728. Aggarwal B (2004). Nuclear factor-[kappa] B: The enemy within. Cancer cell 6: 203-208. Aggarwal B, Ichikawa H (2005). Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell cycle (Georgetown, Tex.) 4: 1201-1215. Aggarwal B, Shishodia S (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochemical pharmacology 71: 1397-1421. Agus D, Akita R, Fox W, Lewis G, Higgins B, Pisacane P et al (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer cell 2: 127-137. Anderton M, Jukes R, Lamb J, Manson M, Gescher A, Steward W et al (2003). Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. Journal of Chromatography B 787: 281-291. Anderton M, Manson M, Verschoyle R, Gescher A, Lamb J, Farmer P et al (2004). Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clinical Cancer Research 10: 5233-5241. Ashcroft M, Ludwig R, Woods D, Copeland T, Weber H, MacRae E et al (2002). Phosphorylation of HDM2 by Akt. Oncogene 21: 1955-1962. Auborn K, Fan S, Rosen E, Goodwin L, Chandraskaren A, Williams D et al (2003). Indole-3-carbinol is a negative regulator of estrogen. Journal of Nutrition 133: 2470S-2475S. Bagheri-Yarmand R, Vadlamudi R, Wang R, Mendelsohn J, Kumar R (2000). Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-β1-mediated angiogenesis. Journal of Biological Chemistry 275: 39451-39457. Barone M, Crozat A, Tabaee A, Philipson L, Ron D (1994). CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes & development 8: 453-464. Baselga J, Swain S (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9: 463-475. Bellacosa A, Kumar C, Cristofano A, Testa J (2005). Activation of AKT kinases in cancer: implications for therapeutic targeting. Advances in Cancer Research 94: 29-86. Benusiglio P (2008). Focus on ERBB2. Pharmacogenomics 9: 825-828. Bhatnagar N, Li X, Chen Y, Zhou X, Garrett S, Guo B (2009). 3, 3′-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prevention Research 2: 581-589. Bhuiyan M, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S et al (2006). Down-regulation of androgen receptor by 3, 3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer research 66: 10064-10072. Bjeldanes L, Kim J, Grose K, Bartholomew J, Bradfield C (1991). Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Proceedings of the National Academy of Sciences of the United States of America 88: 9543-9547. Bradlow H, Michnovicz J, Telang N, Osborne M (1991). Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574. Brandi G, Paiardini M, Cervasi B, Fiorucci C, Filippone P, De Marco C et al (2003). A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer research 63: 4028-4036. Brehm A, Miska E, McCance D, Reid J, Bannister A, Kouzarides T (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597-601. Burgess A, Cho H, Eigenbrot C, Ferguson K, Garrett T, Leahy D et al (2003). An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Molecular cell 12: 541-552. Burstein H, Sun Y, Dirix L, Jiang Z, Paridaens R, Tan A et al (2010). Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. Journal of Clinical Oncology 28: 1301-1307. Cao N, Li S, Wang Z, Ahmed KM et al (2009). NF- Carter T, Liu K, Ralph Jr W, Chen D, Qi M, Fan S et al (2002). Diindolylmethane alters gene expression in human keratinocytes in vitro. Journal of Nutrition 132: 3314-3324. Chambers A, Groom A, MacDonald I (2002). Metastasis: dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer 2: 563-572. Chambers A, Matrisian L (1997). Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute 89: 1260-1270. Chen Y, Law P, Loh H (2005). Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Current Medicinal Chemistry-Anti-Cancer Agents 5: 575-589. Cheng J, Lindsley C, Cheng G, Yang H, Nicosia S (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492. Chinni S, Li Y, Upadhyay S, Koppolu P, Sarkar F (2001). Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20: 2927-2936. Chinni S, Sarkar F (2002). Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clinical Cancer Research 8: 1228-1236. Cho H, Leahy D (2002). Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330-1333. Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney D et al (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760. Citri A, Gan J, Mosesson Y, Vereb G et al (2004). Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO rep. 5: 1165-1170 Cohen J, Kristal A, Stanford J (2000). Fruit and vegetable intakes and prostate cancer risk. JNCI Journal of the National Cancer Institute 92: 61-68. Cornolti G, Ungari M, Morassi M, Facchetti F, Rossi E, Lombardi D et al (2007). Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Archives of Otolaryngology- Head and Neck Surgery 133: 1031-1036. Cover C, Hsieh S, Tran S, Hallden G, Kim G, Bjeldanes L et al (1998). Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. Journal of Biological Chemistry 273: 3838-3847. Cram E, Liu B, Bjeldanes L, Firestone G (2001). Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. Journal of Biological Chemistry 276: 22332-22340. D'souza B, Taylor-Papadimitriou J (1994). Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proceedings of the National Academy of Sciences of the United States of America 91: 7202-7206. Dashwood R (1998). Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? Chemico-biological interactions 110: 1-5. Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241. De Kruif C, Marsman J, Venekamp J, Falke H, Noordhoek J, Blaauboer B et al (1991). Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chemico-biological interactions 80: 303-315. Dhillon A, Hagan S, Rath O, Kolch W (2007). MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290. Eccles S (2001). The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. Journal of mammary gland biology and neoplasia 6: 393-406. Eferl R, Wagner E (2003). AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer 3: 859-868. Fan S, Meng Q, Auborn K, Carter T, Rosen E (2006). BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. British journal of cancer 94: 407-426. Ferguson K, Berger M, Mendrola J, Cho H, Leahy D, Lemmon M (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Molecular cell 11: 507-517. Fernandez-Capetillo O, Nussenzweig A (2004). Linking histone deacetylation with the repair of DNA breaks. Proceedings of the National Academy of Sciences of the United States of America 101: 1427-1428. Firestone G, Bjeldanes L (2003). Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. Journal of Nutrition 133: 2448S-2455S. Frame S, Cohen P (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochemical Journal 359: 1-16. Franklin M, Carey K, Vajdos F, Leahy D, de Vos A, Sliwkowski M (2004). Insights 54 into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer cell 5: 317-328. Frydoonfar H, McGrath D, Spigelman A (2002). Inhibition of proliferation of a colon cancer cell line by indole 3 carbinol. Colorectal Disease 4: 205-207. Frydoonfar H, McGrath D, Spigelman A (2003). The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. ANZ Journal of Surgery 73: 154-156. Garcia H, Brar G, Nguyen D, Bjeldanes L, Firestone G (2005). Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. Journal of Biological Chemistry 280: 8756-8764. Garikapaty V, Ashok B, Tadi K, Mittelman A, Tiwari R (2006). 3, 3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochemical and biophysical research communications 340: 718-725. Gong Y, Xue L, Firestone GL, Bjeldanes LF (2006). 3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Research 66: 4880-4887. Grose K, Bjeldanes L (1992). Oligomerization of indole-3-carbinol in aqueous acid. Chemical research in toxicology 5: 188-193. Grunstein M (1997). Histone acetylation in chromatin structure and transcription. Nature 389: 349-352. Hellyer N, Cheng K, Koland J (1998). ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochemical Journal 333: 757-763. Hennessy B, Smith D, Ram P, Lu Y, Mills G (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 4: 988-1004. Herrmann S, Seidelin M, Bisgaard H, Vang O (2002). Indolo [3, 2-b] carbazole inhibits gap junctional intercellular communication in rat primary hepatocytes and acts as a potential tumor promoter. Carcinogenesis 23: 1861-1868. 55 Higdon J, Delage B, Williams D, Dashwood R (2007). Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacological research 55: 224-236. Hong C, Firestone G, Bjeldanes L (2002). Bcl-2 family-mediated apoptotic effects of 3, 3'-diindolylmethane (DIM) in human breast cancer cells. Biochemical pharmacology 63: 1085-1097. Hong C, Kim H (2002). 3, 3'-Diindolylmethane (DIM) induces a G1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21WAF1/CIP1 expression. Carcinogenesis 23: 1297-1305. Howells L, Gallacher-Horley B, Houghton C, Manson M, Hudson E (2002). Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Molecular cancer therapeutics 1: 1161-1172. Hubbard S (2006). EGF receptor activation: push comes to shove. Cell 125: 1029-1031. Hudson E, Howells L, Gallacher-Horley B, Fox L, Gescher A, Manson M (2003). Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW 480 colon tumour cell line. BMC cancer 3: 2-19. Hynes N, MacDonald G (2009). ErbB receptors and signaling pathways in cancer. Current opinion in cell biology 21: 177-184. Izumi Y, Xu L, Di Tomaso E, Fukumura D, Jain R (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280. Jaehne J, Urmacher C, Thaler H, Friedlander-Klar H, Cordon-Cardo C, Meyer H (1992). Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. Journal of cancer research and clinical oncology 118: 474-479. Jeon K, Rih J, Kim H, Lee Y, Cho C, Goldberg I et al (2003). Pretreatment of 56 indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS letters 544: 246-251. Karin M, Ben-Neriah Y (2000). Phosphorylation meets ubiquitination: the control of NF-κB activity. Annual Review of Immunology 18: 621-663. Katdare M, Osborne M, Telang N (1998). Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncology reports 5: 311-315. Kaufman R (1999). Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes & development 13: 1211-1233. Khwaja FS, Wynne S, Posey I, Djakiew D (2009). 3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res (Phila). 2: 566-571. Kim D, Cheng G, Lindsley C, Yang H, Cheng J (2005). Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Current opinion in investigational drugs (London, England: 2000) 6: 1250-1258. Kim I, Yong H, Kang K, Moon A (2009). Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer letters 275: 227-233. Kim Y, Milner J (2005). Targets for indole-3-carbinol in cancer prevention. The Journal of Nutritional Biochemistry 16: 65-73. Klos KS, Wyszomierski SL, Sun M, Tan M et al (2006). ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer research 66: 2028-2037. Kohle C, Bock K (2007). Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochemical pharmacology 73: 1853-1862. Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M et al (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against 57 HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer research 66: 1630-1639. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim H et al (2008). Mammalian Target of Rapamycin Repression by 3, 3“-Diindolylmethane Inhibits Invasion and Angiogenesis in Platelet-Derived Growth Factor-D–Overexpressing PC3 Cells. Cancer research 68: 1927-1934. Kong D, Li Y, Wang Z, Banerjee S, Sarkar F (2007). Inhibition of angiogenesis and invasion by 3, 30-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Research 67: 3310-3319. Kucharczak J, Simmons M, Fan Y, Gelinas C (2003). To be, or not to be: NF-kB is the answer-role of Rel/NF-kB in the regulation of apoptosis. Oncogene 22: 8961-8982. Lane H, Beuvink I, Motoyama A, Daly J, Neve R, Hynes N (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Molecular and cellular biology 20: 3210-3223. Larsen-Su S, Williams D (2001). Transplacental exposure to indole-3-carbinol induces sex-specific expression of CYP1A1 and CYP1B1 in the liver of Fischer 344 neonatal rats. Toxicological Sciences 64: 162-168. Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O (2008). Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1. Oncol Rep 19: 811-817. Le X, Claret F, Lammayot A, Tian L, Deshpande D, LaPushin R et al (2003). The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. Journal of Biological Chemistry 278: 23441-233450. Leong H, Firestone G, Bjeldanes L (2001). Cytostatic effects of 3, 3'-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-{alpha} expression. Carcinogenesis 22: 1809-1817. 58 Li Y, Li X, Guo B (2010). Chemopreventive Agent 3, 3“-Diindolylmethane Selectively Induces Proteasomal Degradation of Class I Histone Deacetylases. Cancer research 70: 646-654. Li Y, Li X, Sarkar F (2003). Gene expression profiles of I3C-and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. Journal of Nutrition 133: 1011-1019. Li Y, Wang Z, Kong D, Murthy S, Dou Q, Sheng S et al (2007). Regulation of FOXO3a/℃-catenin/GSK-3℃ signaling by 3, 3“-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. Journal of Biological Chemistry 282: 21542-21550. Lian J, Word B, Taylor S, Hammons G, Lyn-Cook B (2004). Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer research 24: 133-137. Liu E, Thor A, He M, Barcos M, Ljung B, Benz C (1992). The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7: 1027-1032. Liu H, Wormke M, Safe S (1994). Indolo [3, 2-b] carbazole: a dietary-derived factor that exhibits both antiestrogenic and estrogenic activity. Journal of the National Cancer Institute 86: 1758-1765. Lokker N, Sullivan C, Hollenbach S, Israel M, Giese N (2002). Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells. Cancer research 62: 3729-3735. Longva K, Pedersen N, Haslekas C, Stang E, Madshus I (2005). Herceptin induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down regulation of ErbB2. International Journal of Cancer 116: 359-367. Luo R, Postigo A, Dean D (1998). Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473. Marciniak S, Ron D (2006). Endoplasmic reticulum stress signaling in disease. Physiological reviews 86: 1133-1149. Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W (2001). Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer 1: 194-202. McGuire K, Ngoubilly N, Neavyn M, Lanza-Jacoby S (2006). 3, 3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 132: 208-213. Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology 21: 2787-1799. Minella A, Clurman B (2005). Mechanisms of tumor suppression by the SCF (Fbw7). Cell cycle (Georgetown, Tex.) 4: 1356-1359. Minich D, Bland J (2007). A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutrition reviews 65: 259-267. Molina M, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer research 61: 4744-4749. Mulvey L, Chandrasekaran A, Liu K, Lombardi S, Wang X, Auborn K et al (2007). Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Molecular Medicine 13: 69-78. Murphy L, MacKeigan J, Blenis J (2004). A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Molecular and cellular biology 24: 144-153. Murphy L, Smith S, Chen R, Fingar D, Blenis J (2002). Molecular interpretation of ERK signal duration by immediate early gene products. Nature cell biology 4: 556-564. Nachshon-Kedmi M, Yannai S, Fares F (2004). Induction of apoptosis in human prostate cancer cell line, PC3, by 3, 3“-diindolylmethane through the mitochondrial pathway. British journal of cancer 91: 1358-1363. 60 Nachshon-Kedmi M, Yannai S, Haj A, Fares F (2003). Indole-3-carbinol and 3, 30-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41: 745-52. Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A et al (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer cell 6: 117-127. Narlikar G, Fan H, Kingston R (2002). Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487. Nechushtan A, Smith C, Yi-Te Hsu R (1999). Conformation of the Bax C-terminus regulates subcellular location and cell death. The EMBO journal 18: 2330-2341. Niu G, Carter WB (2007). Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer research 67: 1487-1493. Ociepa-Zawal M, Rubis B, Lacinski M, Trzeciak W (2007). The effect of indole-3-carbinol on the expression of CYP1A1, CYP1B1 and AhR genes and proliferation of MCF-7 cells. Acta Biochim Pol 54: 113-117. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K et al (2002). Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Journal of Biological Chemistry 277: 21843-21850. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J et al (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787. Olayioye M, Neve R, Lane H, Hynes N (2000). NEW EMBO MEMBERS'REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer. Science's STKE 19: 3159-3167. Owens M, Horten B, Da Silva M (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical Breast Cancer 5: 63-69. 61 Park K, Han S, Kim H, Kim J, Shin E (2006). HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48: 702-707. Parkin D, Malejka-Giganti D (2004). Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3, 3'-diindolylmethane and its parent compound indole-3-carbinol. Cancer detection and prevention 28: 72-79. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. The EMBO journal 15: 2452.-2467 Pratt W, Toft D (2003). Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Experimental biology and medicine (Maywood, NJ) 228: 111-133. Prigent S, Gullick W (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. The EMBO journal 13: 2831-2841. Rahman K, Ali S, Aboukameel A, Sarkar S, Wang Z, Philip P et al (2007). Inactivation of NF-κB by 3, 3“-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Molecular cancer therapeutics 6: 2757-2765. Rahman K, Aranha O, Sarkar F (2003). Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutrition and cancer 45: 101-112. Rahman K, Li Y, Wang Z, Sarkar S, Sarkar F (2006). Gene expression profiling revealed survivin as a target of 3, 3“-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer research 66: 4952-4960. Rahman K, Sarkar F (2005). Inhibition of nuclear translocation of nuclear factor-℃B contributes to 3, 3“-diindolylmethane-induced apoptosis in breast cancer cells. Cancer research 65: 364-371. 62 Rajoria S, Suriano R, Wilson YL, Schantz SP (2010). 3,3'-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep 25: 491-497. Rao R, Ellerby H, Bredesen D (2004). Coupling endoplasmic reticulum stress to the cell death program. Cell Death & Differentiation 11: 372-380. Reed G, Arneson D, Putnam W, Smith H, Gray J, Sullivan D et al (2006). Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3, 3“-diindolylmethane. Cancer Epidemiology Biomarkers & Prevention 15: 2477-2481. Rogan EG (2006). The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 20: 221-228. Ross J, Fletcher J (1998). The HER 2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells 16: 413-428. Rusnak D, Lackey K, Affleck K, Wood E, Alligood K, Rhodes N et al (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Molecular cancer therapeutics 1: 85-94. Sarkar F, Li Y (2004). Indole-3-carbinol and prostate cancer. Journal of Nutrition 134: 3493S-3498S. Sato A, Fujita N, Tsuruo T (2000). Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America 97: 10832-10837. Schechter A, Stern D, Vaidyanathan L, Decker S, Drebin J, Greene M et al (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516. Schulte T, Neckers L (1998). The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer chemotherapy and pharmacology 42: 63 273-279. Shaw R, Cantley L (2006). Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 441: 424-430. Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N et al (1996). Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13: 883-889. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. Spector N, Xia W, Burris H, Hurwitz H, Dees E, Dowlati A et al (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Journal of Clinical Oncology 23: 2502-2512. Stiles B (2009). PI-3-K and AKT: Onto the mitochondria. Advanced drug delivery reviews 61: 1276-1282. Stresser D, Williams D, Griffin D, Bailey G (1995). Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metabolism and Disposition 23: 965-975. Sun S, Han J, Ralph Jr W, Chandrasekaran A, Liu K, Auborn K et al (2004). Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell stress & chaperones 9: 76-87. Sundar S, Kerekatte V, Equinozio C, Doan V, Bjeldanes L, Firestone G (2006). Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells. Molecular Endocrinology 20: 3070-3782. Takada Y, Andreeff M, Aggarwal B (2005). Indole-3-carbinol suppresses NF-{kappa} B and I {kappa} B {alpha} kinase activation, causing inhibition of expression of NF-{kappa} B-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106: 641-649. 64 Takeuchi K, Ito F (2010). EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR targeting tyrosine kinase inhibitors. FEBS Journal 277: 316-326. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S et al (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and cellular biology 16: 5276-5287. Ustach C, Kim H (2005). Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Molecular and cellular biology 25: 6279-6288. Ustach C, Taube M, Hurst N, Bhagat S, Bonfil R, Cher M et al (2004). A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer research 64: 1722-1729. Van Laethem A, Van Kelst S, Lippens S, Declercq W, Vandenabeele P, Janssens S et al (2004). Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes. The FASEB Journal 18: 1946-1948. Verhoeven D, Goldbohm R, van Poppel G, Verhagen H, van den Brandt P (1996). Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiology Biomarkers & Prevention 5: 733-748. Vermeij J, Teugels E, Bourgain C, Xiangming J (2008). Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC cancer 8: 3-11. Vivar OI, Lin CL, Firestone GL, Bjeldanes LF (2009). 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol.78: 469-476. Wagner E, Nebreda A (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer 9: 537-549. Wang T, Milner M, Milner J, Kim Y (2006). Estrogen receptor [alpha] as a target for indole-3-carbinol. The Journal of Nutritional Biochemistry 17: 659-664. Wang Z, Ahmad A, Li Y, Kong D, Azmi A, Banerjee S et al (2010). Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochimica et Biophysica Acta 1806: 122-130. Wang Z, Kong D, Banerjee S, Li Y, Adsay N, Abbruzzese J et al (2007). Down-regulation of Platelet-Derived Growth Factor-D Inhibits Cell Growth and Angiogenesis through Inactivation of Notch-1 and Nuclear Factor-κB Signaling. Cancer research 67: 11377-11385. Weng J, Tsai C, Kulp S, Chen C (2008). Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer letters 262: 153-163. Weng J, Tsai C, Kulp S, Wang D, Lin C, Yang H et al (2007). A Potent Indole-3-Carbinol–Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling Pathways in Prostate Cancer Cells. Cancer research 67: 7815-7824. Weston C, Davis R (2002). The JNK signal transduction pathway. Current opinion in genetics & development 12: 14-21. Wilson A, Byun D, Popova N, Murray L, L'Italien K, Sowa Y et al (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry 281: 13548-13558. Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D et al (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erkl/2 and AKT pathways. Oncogene 21: 6255-6263. Xin M, Deng X (2005). Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. Journal of Biological Chemistry 280: 10781. Xiong S, Grijalva R, Zhang L, Nguyen N, Pisters P, Pollock R et al (2001). Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-β1-activated p38 signaling pathway enhances endothelial cell migration. Cancer research 61: 1727-1732. 66 Xu L, Tong R, Cochran D, Jain R (2005). Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer research 65: 5711-5719. Xue L, Firestone GL, Bjeldanes LF (2005). DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343-2353 Yamaguchi H, Wang H (2001). The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20: 7779-7786. Yarden Y, Sliwkowski M (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2: 127-137. Yaziji H, Goldstein L, Barry T, Werling R, Hwang H, Ellis G et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. Jama 291: 1972-1977. Yoeli-Lerner M, Toker A (2006). Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell cycle 5: 603-605. Yoon S, Seger R (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44. Yu D, Hamada J, HONG Z, Nicolson G (1992). Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263-2270. Yu D, Hung M (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121. Zhang X, Gureasko J, Shen K, Cole P, Kuriyan J (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149. Zheng F, Kuduk S, Chiosis G, Munster P, Sepp-Lorenzino L, Danishefsky S et al (2000). Identification of a geldanamycin dimer that induces the selective degradation 67 of HER-family tyrosine kinases. Cancer research 60: 2090-2094. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H et al (2002). Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. Journal of cancer research and clinical oncology 128: 539-546. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W et al (2007). FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129: 1275-1286. |
論文全文使用權限 |
如有問題,歡迎洽詢!
圖書館數位資訊組 (02)2621-5656 轉 2487 或 來信